Helen & Robert Appel Alzheimer’s Disease Research Institute

You are here

Laboratories

Dr. Paul and team

Dr. Paul and team

The Paul Laboratory

The Paul Laboratory studies the fundamental disease biology of Alzheimer's disease with the ultimate goal of translating this understanding to the discovery and development of disease-modifying therapies. The work in our laboratory is multifaceted and involves very basic cellular-molecular studies using a variety of cell-based in vitro models (both of neurons and glia) as well as in vivo work involving the creation and characterization of a number of transgenic mouse models of Alzheimer's disease-related neuropathology. Read more

The role of Hsp90 in Alzheimer’s disease

Principal Investigator:
Wenjie Luo, PhD

National Institutes of Health/National Institute on Aging Grant

The overall objective is to provide new therapeutic strategies for AD treatment. Based on our preliminary data, our studies demonstrate that Hsp90 binds to mutant APP and regulates its metabolism. Therefore, we hypothesize that Hsp90 is critical in dysregulated APP processing and modulates the progression of AD.  We characterize the regulatory roles of Hsp90 in amyloid generation by investigating the dynamic Hsp90-APP interaction and its impact on APP processing/trafficking. Then finally, the therapeutic effects of Hsp90 inhibitors will be determined in a mouse model of AD.

Genomic analysis of bipolar disorder in a genetic isolate (NIH/NIMH R01 Grant)

Principal Investigator:
Steven Paul, MD

National Institutes of Health/National Institute of Mental Health Grant

To identify and fully elaborate genetic variants that underlie the susceptibility to develop a highly heritable form of mental illness, bipolar affective disorder in a well-studied and phenotyped genetic isolate, the Old Order Amish.

Treatments for Alzheimer’s disease

Principal Investigator:
Steven Paul, MD

Johnson & Johnson Pharmaceuticals

To discover a human or humanized anti-tau monoclonal antibody which recognizes a pathological tau conformation (s) and readily blocks the propagation of misfolded tau protein in vivo and the resulting neurodegeneration and disease progression which characterizes Alzheimer’s disease (AD).

Apolipoprotein E biology in Alzheimer's disease

Principal Investigator:
Steven Paul, MD

AstraZeneca Pharmaceuticals

To advance our fundamental knowledge of the role apoE plays in the etiology and pathogenesis of AD, i.e. in order to delineate one or more novel drug targets for potentially treating and (or) preventing AD.

Gene delivery of apolipoprotein E2 as a treatment for Alzheimer's disease

Principal Investigator:
Steven Paul, MD

Alzheimer’s Drug Discovery Foundation (ADDF)

To quantify the effects of apoE2 expression on brain Aβ/amyloid burden by comparing the effects of both intracerebral as well as intraventricular gene delivery of apoE2 using two viral vectors (AAV2 and lentivirus) on apoE2 expression and brain amyloid burden in the PDAPP mouse model of Alzheimer’s disease. 

In this project we extended our earlier studies on apoE2 gene delivery as a potential treatment strategy for AD by using an optimized and well-studied viral vector(s) and exploring relatively non-invasive routes of CNS administration. Specifically, we will explore the utility of the Rhesus serotype adeno-associated viral vector (AAVrh.10) and two different delivery approaches or routes of administration (e.g. direct intracerebral/intraparenchymal and intracisternal) in mice (using a new and more relevant transgenic AD mouse model) to facilitate an eventual clinical trial of apoE2 gene delivery in AD patients.

Investigating the role of microglia in tau clearance in Alzheimer's disease

Principal Investigator:
Dr. Wenjie Luo

Coins for Alzheimer's Research Trust (CART)

This project focuses on characterization of the cellular pathways and regulatory mechanisms involved in tau clearance by microglia. The data generated from this study will help address several fundamental questions regarding tau clearance by microglia and will provide novel therapeutic interventions for treating Alzheimer's disease by targeting a microglial-mediated tau clearance pathway.


Dr. Petsko and team.

Dr. Petsko and team.

The Petsko Laboratory

During the past 10 years, Dr. Petsko has pursued groundbreaking research not only on how proteins work, but how they are related to the causes of neurodegenerative diseases. Using the techniques of genetics, structural biology, and structure-guided drug discovery, his laboratory is able to identify, validate, and exploit novel targets for the treatment of age-related neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Lou Gehrig’s diseases. Read more

Stabilization of alpha-synuclein as therapeutic strategy for Parkinson's disease

Principal Investigator:
Gregory A. Petsko, D. Phil.

The Michael J. Fox Foundation for Parkinson’s Research Grant

The overall objective of this grant is to complete the NMR structure determination of a new, tetrameric form of alpha-synuclein discovered in this lab and repeat the structure determination for one or more of the Parkinson’s Disease-associated mutants of the protein.  It is further proposed to verify that this form exists in neurons and that the ratio of this form to that of the fibrilar form of the protein changes with the inset and progression of Parkinson’s Disease, thereby validating stabilization of the tetramer as a novel approach to the prevention of the disease, and to develop inhibitors to block the proteolytic processing of the protein.

Mechanisms of Enzymic Proton and Hydride Transfers

Principal Investigator:
Dr. Gregory A. Petsko

National Institutes of Health/National Institute of General Medicinal Sciences Grant

The overall objective of this project is to use time-resolved and other forms of protein crystallography to achieve an understanding of the structural basis for efficient enzymic catalysis of hydrogen transfer from weakly acidic carbon and oxygen centers. 

High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1

Principal Investigator:
Dr. Gregory A. Petsko

National Institutes of Health

The goal of this project is to identify compounds that suppress the toxicity fo fUS/TLS to motor neurons, and to find small molecules that either stabilize the dimeric form of superoxide dismutase or lower its expression in the central nervous system.

The Role of FUS/TLS in Familial Amytrophic Lateral Sclerosis by Studies in a Model Organism

Principal Investigator:
Dr. Gregory A. Petsko

ATA - The ALS Therapeutic Alliance

The overall objective of this proposal is to develop a system in a model organism that permits genetic and biochemical studies of the role of the protein FUS/TLS in the neurologic disease ALS, and to exploit that system both for such studies and as a vehicle for high-throughput screening for drugs that may ameliorate FUS/TLS-induced cytotoxicity.  In parallel, studies of the structure of FUS/TLS will be carried out with the aim of using in silico screening to find drugs that will stabilize the nuclear-bound form of the protein.

New Approaches to the Prevention and Treatment of Neurologic Disorders

Principal Investigator:
Dr. Gregory A. Petsko

Fidelity Biosciences Research Initiative (FBRI)

The overall objective is to identify, functionally characterize, and exploit new targets for the prevention and treatment of several neurologic disorders, with emphasis on Alzheimer’s, Parkinson’s and Lou Gehrig’s diseases.

Effect of APOE on CNS Neurons: Role of LRP

Principal Investigator:
Gregory A. Petsko, D. Phil.

National Institute of Neurological Disorders & Stroke (NINDS)

This research project is aimed at investigating several aspects of the "disease biology" of Alzheimer's disease (AD) with an overall goal of developing disease-modifying therapies to treat or prevent AD. This is accomplished by using a variety of transgenic mouse models of AD pathology shown to have apoE isoform-dependent effects on brain amyloid deposition/burden (apoE4>apoE3>>apoe2) in aging mutant APP transgenic mice. This approach closely recapitulates what is observed in humans who have high genetic risk (apoE4 carriers) for AD (measured by PET imaging).

Novel gene therapy modality increasing retromer expression

Principal Investigator:
Gregory A. Petsko, D. Phil.

Meira GTx (12/5/2016-12/4/2019)

The main goal of this project is to identify ALL of the genes that regulate retromer function in mammalian cells, not just at the level of transcription, but also in terms of mRNA stability, translation control, protein half-lives, and biochemical function.

Investigating genes that suppress the proteotoxicity of FUS/TLS and TDP-43

Principal Investigator:
Gregory A. Petsko, D. Phil.

Meira GTx (7/7/2015-7/6/2017)

We propose a focused program to investigate the scope of hUPF1 and hUPF2-mediated suppression of ALS-related protein cytotoxicity, with an emphasis on establishing the mechanism by which it works and identifying additional suppressor genes.

Gene therapeutic modulation of NMD for treatment of ALS

Principal Investigator:
Gregory A. Petsko, D. Phil.

Target ALS Foundation (1/1/2017-12/31/2017)

The goals of this project is to confirm the efficacy of NMD modulation in ALS model animals and to find the optimum form of either hUPF1 or hUPF2 for gene therapy use in the human disease.The ideal construct would have maximal therapeutic efficacy at doses nowhere near any toxic level. For this purpose, we propose to create three new variants of both proteins: catalytically dead, more stable, and with improved NMD function.

Weill Cornell Medicine Helen & Robert Appel Alzheimer’s Disease Research Institute 413 East 69th Street New York, NY 10021 Phone: (646) 962-6323 Fax: (646) 962-0579